Aline Talhouk
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Year:
2026
Background/Objectives: With the rising incidence of obesity-related endometrial cancer, there is renewed interest in physiologic, low-cost approaches to identify women with hormonally active endometrium who may benefit from early preventive interventions. The progesterone challenge test (PCT), an established clinical tool for evaluating amenorrhea, has been previously proposed as a method to detect endometrial pathology. This study systematically evaluated the diagnostic accuracy of the PCT for detecting endometrial hyperplasia, intraepithelial neoplasia, and carcinoma in asymptomatic postmenopausal women to determine its potential role as a physiologic marker of endometrial cancer risk. Methods: A systematic review and meta-analysis were conducted following PRISMA-DTA guidelines. MEDLINE, EMBASE, EBM Reviews, and CINAHL were searched from inception to 20 January 2025, along with ClinicalTrials.gov and grey literature. Eligible studies prospectively evaluated the PCT with endometrial biopsy as the reference standard. Data extraction and risk-of-bias assessment were performed in duplicate. Risk of bias was assessed using QUADAS-2. Pooled sensitivity, specificity, and predictive values were estimated using hierarchical summary receiver operating characteristic models. Results: Nineteen studies (n = 3902) met the inclusion criteria. The pooled sensitivity and specificity of the PCT for detecting endometrial pathology were 95% (95% CI 86–100%) and 87% (76–96%), respectively. The positive predictive value was 32% (95% CI, 16–50%) and the negative predictive value was 100% (100–100%). When endometrial proliferation was included in the target condition, sensitivity decreased to 82%, but positive predictive value increased to 70%. Conclusions: The PCT shows high diagnostic accuracy for identifying estrogen-driven endometrial pathology in asymptomatic postmenopausal women. Re-evaluating this simple, physiologic test as a functional risk-stratification tool could inform precision prevention strategies for endometrial cancer.
Year:
2026
Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.
Year:
2025
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
Year:
2025
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
Year:
2025
Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Year:
2025
Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%–20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumor-initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex IHC and immunofluorescence, we examine the prevalence of T-cell lineage, B-cell lineage, macrophages, and populations with programmed cell death protein 1 or programmed death-ligand 1 across subtypes of ENOC. Results: Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden ( POLE mut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (overall survival P > 0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular profile (NSMP) subtype, where immune infiltrates lacking B cells (TIL B minus ) had inferior outcome (disease-specific survival: HR, 4.0; 95% confidence interval, 1.1–14.7; P Conclusions: Subtype stratification is critical for better understanding of ENOC, in particular the distribution and prognostic significance of immune cell infiltrates. The role of B cells in the immune response within NSMP tumors warrants further study.
Year:
2025
Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas (EC) including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, though tumor initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex immunohistochemistry and immunofluorescence, we examine the prevalence of T cell lineage, B cell lineage, macrophages, and populations with PD-1 or PD-L1 across subtypes of ENOC. Results: Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden ( POLE mut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (OS p>0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular subtype (NSMP) subtype, where immune infiltrates lacking B cells (TIL B minus ) had inferior outcome (DSS HR:4.0 CI 1.1-14.7, p
Year:
2024
Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.
Year:
2024
Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (69)
Jessica N. McAlpine
Chew Wei Chair Gynecologic Oncology, Division Head
The University of British Columbia
Laurence Bernard
McGill University Health Centre
Charlie Gourley
University of Edinburgh
Sue K. Park
Professor
Seoul National University College of Medicine
Kathryn Terry
Co-Scientific Director
Boston Children's Hospital
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Beth Karlan
Vice Chair
University of California, Los Angeles
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Matthew Wakefield
University of Melbourne
Martin Widschwendter
Professor; Director
University of Innsbruck
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Martin Köbel
Associate Professor
University of Calgary
Estrid V. Hoegdall
University of Copenhagen
Paul Timpson
Co-Director ACRF (INCITe) Centre
Garvan Institute of Medical Research
James D Brenton
University of Cambridge
Jae-Weon Kim
Professor
Seoul National University Hospital
Cezary Cybulski
Pomeranian Medical University
Lyndal Anderson
University of Western Sydney
Claus Høgdall
Professor in Clinical Gynecologic Oncology
University of Copenhagen
Lindsay J Collin
Assistant Professor
Emory University
Jalid Sehouli
Charité - Universitätsmedizin Berlin
Anthony Gill
University of Sydney
Linda Cook
Professor
University of Colorado Cancer Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Parham Minoo
Associate Clinical Professor of Pathology
University of Calgary
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Nicholas Hawkins
Emeritus Professor
UNSW Sydney
Usha Menon
Professor of Gynaecological Oncology
University College London
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jae-Hoon Kim
Yonsei University College of Medicine
Anna H. Wu
Professor
University of Southern California
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Kylie-Ann Mallitt
Senior Lecturer in Biostatistics
University of Sydney
Dale Garsed
University of Melbourne
Philip Crowe
Professor Surgery
University of New South Wales
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Tomasz Huzarski
Pomeranian Medical University
Byoung-Gie Kim
Sungkyunkwan University School of Medicine
Dane Cheasley
Senior Research Fellow
University in Western Australia
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Caroline X Gao
Associate Professor in Biostatistics
University of Melbourne
Jennifer Anne Doherty
Professor
University of Utah
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Kylie L Gorringe
Group Leader
Peter MacCallum Cancer Institute
Jan Lubiński
Head of Dept
Pomeranian Medical University
Mona El-Bahrawy
Imperial College London
Aleksandra Gentry-Maharaj
University College London
David G. Huntsman
The University of British Columbia
Janusz Menkiszak
Head of the University Clinic
Pomeranian Medical University
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Paul Cohen
University of Western Australia
David Lawson Morris
Professor of Surgery
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.